Notch3 Promotes Docetaxel Resistance in Prostate Cancer: A Potential Therapeutic Target Identified

https://pubmed.ncbi.nlm.nih.gov/38115797

NOTCH3 promotes docetaxel resistance in prostate cancer by regulating TUBB3 and the MAPK signaling pathway, suggesting it could be a potential therapeutic target for docetaxel-resistant prostate cancer.